FDA is asking for public comments on what could be done to improve the participation of racial and ethnic demographic subgroup populations in clinical trials, but the effort may not satisfy some stakeholders who want the agency to be more aggressive in encouraging broader enrollment.
In a Federal Register notice slated for publication on Feb